<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9226">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05702489</url>
  </required_header>
  <id_info>
    <org_study_id>ZX-7101A-202</org_study_id>
    <nct_id>NCT05702489</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of ZX-7101A Tablets in Adults With Uncomplicated Influenza</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of ZX-7101A Tablets in Adults With Uncomplicated Influenza</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Zenshine Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Zenshine Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to compare ZX-7101A in Chinese Adults patients with&#xD;
      uncomplicated influenza. The main questions it aims to answer are:&#xD;
&#xD;
        -  The efficacy of ZX-7101A in Chinese Adults patients with uncomplicated influenza.&#xD;
&#xD;
        -  The safety of ZX-7101A in Chinese Adults patients with uncomplicated influenza.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2022</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The time to the remission of all influenza symptoms (hours)</measure>
    <time_frame>from accepting ZX-7101A until the 15 days after the first dosing</time_frame>
    <description>Defined as the time from the start of study treatment to the time all flu symptoms are relieved. Symptom relief was defined as all seven influenza symptoms assessed by the subject on the subject diary card(Stuffy nose, sore throat, cough, muscle or joint pain, fatigue, headache, fever or chills/sweating) were 0 (asymptomatic) or 1 (mild);</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0</measure>
    <time_frame>from accepting ZX-7101A until the 15 days after the first dosing</time_frame>
    <description>The Number of Participants with Treatment-Related Adverse Event will be evalated as the change of vital signs, electrocardiogram (P Wave, QRS Complex, QT Interval), physical examination, and Laboratory test compared with the baseline.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>ZX-7101A low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg, tablet, single oral administration when the subject screened successfully</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZX-7101A high dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 mg, tablet, single oral adminitration when the subject screened successfully</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Analog tablet with no active ingredient, single oral administration when the subject screened successfully</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZX-7101A</intervention_name>
    <description>a drug to treatment influenza in Chinese adults</description>
    <arm_group_label>Placebo control</arm_group_label>
    <arm_group_label>ZX-7101A high dose group</arm_group_label>
    <arm_group_label>ZX-7101A low dose group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 to ≤64 years of age at the time of signing the ICF.&#xD;
&#xD;
          -  Patients in the screening period met the following criteria: (1) rapid influenza&#xD;
             diagnostic test (RIDT) or polymerase chain reaction (PCR) test positive; (2) fever ≥&#xD;
             37.3℃ (axillary temperature) at screening; if taking antipyretics, axillary&#xD;
             temperature ≥ 37.3℃ after taking the drug (more than 4 hours). (3) At least one of&#xD;
             flu-related systemic symptoms is moderate or greater in severity: a. muscle or joint&#xD;
             pain, b. fatigue, c. headache, d. fever. (4) At least one of the influenza-related&#xD;
             respiratory symptoms is moderate or greater in severity: a. nasal congestion, b. sore&#xD;
             throat, c. cough.&#xD;
&#xD;
          -  The first occurrence of influenza symptoms ≤ 48 hours from the time of patient&#xD;
             randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with influenza virus infection requiring hospitalization.&#xD;
&#xD;
          -  High-risk population.&#xD;
&#xD;
          -  Bronchitis, pneumonia, pleural effusion or interstitial disease suspected by a&#xD;
             clinician or confirmed by chest imaging [X-ray (anteroposterior or&#xD;
             anteroposterior)/CT] and judged clinically significant by the investigator at&#xD;
             screening.&#xD;
&#xD;
          -  Patients who have developed acute respiratory tract infection, otitis media, and&#xD;
             sinusitis within 2 weeks before screening.&#xD;
&#xD;
          -  Patients with other infections requiring systemic anti-infective treatment, or blood&#xD;
             routine examination at screening: white blood cell count (WBC) &gt; 10.0 × 109/L.&#xD;
&#xD;
          -  Patients with purulent sputum or suppurative tonsillitis.&#xD;
&#xD;
          -  Those who have difficulty in swallowing drugs or have a history of gastrointestinal&#xD;
             diseases that seriously affect drug absorption.&#xD;
&#xD;
          -  Medications against influenza virus within 7 days prior to Screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>hong wen Zhang, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>hong Wen Zhang, doctor</last_name>
    <phone>5288123</phone>
    <email>zhangwenhong202208@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Zhang, doctor</last_name>
    <phone>52887926</phone>
    <email>Zhangj_fudan@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongshan Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>bi jie Hu, Doctoral candidate</last_name>
      <phone>13601621604</phone>
      <email>hu.bijie@zs-hospital.sh.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 16, 2023</study_first_submitted>
  <study_first_submitted_qc>January 25, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2023</study_first_posted>
  <last_update_submitted>January 25, 2023</last_update_submitted>
  <last_update_submitted_qc>January 25, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

